医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

R-Tech Ueno

R-Tech Ueno: Announcement on Collaborative Development of Therapeutic Agent for Cerebral Infarction Utilizing VAP-1 Inhibitor (RTU-009) with Autonomous University of Barcelona and Vall d’Hebron Institute of Research

R-Tech Ueno: Announcement on Collaborative Development of Therapeutic Agent for Cerebral Infarction Utilizing VAP-1 Inhibitor (RTU-009) with Autonomous University of Barcelona and Vall d’Hebron Institute of Research

その他ヘルスヘルスケア眼科医療臨床試験製薬　 TimeLine: Agent for Cerebral Infarction Utilizing VAP-1 Announcement on Collaborative Development Autonomous University of Barcelona and Vall R-Tech Ueno

2015年06月08日

R-Tech Ueno: Announcement on Completion of the Phase I Single-Dose Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096

R-Tech Ueno: Announcement on Completion of the Phase I Single-Dose Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096

ヘルスケア眼科医療臨床試験製薬　 TimeLine: Announcement on Completion of the Phase I Clinical Trial for the Novel VAP-1 Inhibitor R-Tech Ueno

2015年05月25日

R-Tech Ueno: Announcement on Collaborative Development of Therapeutic Agent for Diabetic Retinopathy and Diabetic Macular Edema Utilizing VAP-1 Inhibitor (RTU-1096) with Hokkaido University

R-Tech Ueno: Announcement on Collaborative Development of Therapeutic Agent for Diabetic Retinopathy and Diabetic Macular Edema Utilizing VAP-1 Inhibitor (RTU-1096) with Hokkaido University

ヘルスケア眼科医療糖尿病臨床試験製薬　 TimeLine: Agent for Diabetic Retinopathy and Diabetic Announcement on Collaborative Development R-Tech Ueno VAP-1 Inhibitor with Hokkaido University

2015年05月18日

R-Tech Ueno: Termination of License Agreements for Unoprostone

R-Tech Ueno: Termination of License Agreements for Unoprostone

ヘルスケア眼科医療製薬　 TimeLine: R-Tech Ueno Termination of License Agreements for Unoprostone

2015年05月07日

R-Tech Ueno: Announcement on Acquisition of the Right to Develop and Commercialize DE-105 from Santen Pharmaceutical Co., Ltd.

R-Tech Ueno: Announcement on Acquisition of the Right to Develop and Commercialize DE-105 from Santen Pharmaceutical Co., Ltd.

ヘルスケアヘルス一般眼科医療臨床試験製薬　 TimeLine: Announcement on Acquisition of the Right Commercialize DE-105 from Santen Pharmaceutical Co R-Tech Ueno

2015年04月27日

R-Tech Ueno: The End of a Phase 3 Clinical Study and Preliminary Findings from a Phase 3 of Unoprostone (Development Code UF-021) for Treatment of Retinitis Pigmentosa

R-Tech Ueno: The End of a Phase 3 Clinical Study and Preliminary Findings from a Phase 3 of Unoprostone (Development Code UF-021) for Treatment of Retinitis Pigmentosa

バイオテクノロジーヘルスケア眼科医療臨床試験製薬　 TimeLine: Development Code UF-021 Findings from a Phase 3 of Unoprostone R-Tech Ueno The End of a Phase 3 Clinical Treatment of Retinitis Pigmentosa

2015年03月09日

R-Tech Ueno: Lawsuit Claiming Infringement of AMITIZA® Capsules Patents

R-Tech Ueno: Lawsuit Claiming Infringement of AMITIZA® Capsules Patents

その他ヘルスヘルスケア眼科医療製薬　 TimeLine: Capsules Patents Lawsuit Claiming Infringement of AMITIZA R-Tech Ueno

2014年11月13日

R-Tech Ueno: Completion of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in the US for the Treatment of Severe Dry Eye

R-Tech Ueno: Completion of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in the US for the Treatment of Severe Dry Eye

バイオテクノロジーヘルスケア眼科医療臨床試験製薬　 TimeLine: Completion of a Phase I Human Serum Albumin-Containing Ophthalmic Solution II Clinical Study of Recombinant in the US for the Treatment R-Tech Ueno

2014年11月10日

R-Tech Ueno: Sucampo and Takeda Enter into Global Licensing Agreement for AMITIZA® (lubiprostone)

R-Tech Ueno: Sucampo and Takeda Enter into Global Licensing Agreement for AMITIZA® (lubiprostone)

その他ヘルスヘルスケア眼科医療製薬　 TimeLine: R-Tech Ueno Sucampo and Takeda Enter into Global Licensing

2014年10月23日

R-Tech Ueno: Announcement of Initiation of the Phase I Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096

R-Tech Ueno: Announcement of Initiation of the Phase I Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096

バイオテクノロジーヘルスケアヘルス一般眼科医療臨床試験製薬　 TimeLine: Announcement of Initiation of the Phase I for the Novel VAP-1 Inhibitor RTU-1096 R-Tech Ueno

2014年10月20日